Why the willingness to hold longer than the market expects has become one of the few durable edges left in growth investing.
Most of what passes for edge in growth investing today is really just speed — faster diligence, faster terms, faster closes. Speed is easy to compete away. Patience is not. It requires a willingness to hold a position through periods when the market is impatient, distracted, or simply looking elsewhere, and to trust that the value being built will eventually be recognized.
This is not a passive virtue. Patient capital still underwrites rigorously, still structures carefully, and still expects a return. What it does not do is force a company's timeline to match a fund's calendar. Many of the businesses most worth backing — those solving genuinely hard problems, building durable infrastructure, or repositioning an entire category — simply cannot be rushed to scale without damaging what made them valuable in the first place.
The market's impatience is, in effect, a mispricing opportunity. Capital that insists on quick outcomes systematically underweights businesses whose value curve is longer and steeper than average. Capital that can wait captures that gap. This is the core of our thesis: the willingness to be patient is not a constraint on returns, it is a source of them.
In practice, this means we structure our investments — sizing, oversight, and hold period — around the company's actual trajectory rather than a fixed fund timeline. It means resisting the urge to force an exit before a business has fully compounded. And it means being comfortable holding a position quietly, without needing to justify it every quarter.
Patience, applied with discipline, is not the absence of urgency. It is the recognition that the right outcome and the fast outcome are rarely the same thing — and that our advantage lies in consistently choosing the former.